medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2022, Number 1

<< Back Next >>

Rev Biomed 2022; 33 (1)

Bone metabolism and osteoporosis: concepts and functions

Pacheco-Pantoja EL, Salazar-Ciau P, Yáñez-Pérez V

Language: Spanish
References: 47
Page: 22-32
PDF size: 197.93 Kb.


ABSTRACT

Our bones play a versatile role in our organism: from providing structure for the body, protection for organs, to serve as mineral stores, such as calcium and phosphorous, which are essential for bone development and stability. The skeleton reaches peak bone mass around age 30, after which they begin to decrease steadily. Although peak bone mass is highly determined by genetics, many modifiable factors can influence skeletal health, such as nutrition, exercise, certain diseases or medications. During lifetime, bones are remodeled, in a process where activated osteoclasts are able to reabsorb the mineralized surface and replace it with new bone produced by the osteoblasts. An impairment in this delicate balance can result in the pathophysiological changes appreciated in osteoporosis. In this descriptive review, a search was made in PubMed and aims to address concepts related to bone metabolism, osteoporosis, as well as the existent treatments of choice, focusing on bisphosphonates, particularly ibandronate.


REFERENCES

  1. Florencio-Silva R, Rodrigues da Silva Sasso G, Sasso- Cerri E, Simoes MJ, Sérgio-Cerri P. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int. 2015; 2015: 1-17. https:// doi.org/10.1155/2015/421746

  2. Kenkre JS, Bassett J. The bone remodelling cycle. Ann Clin Biochem. 2018; 55(3): 308-327. https://doi. org/10.1177/0004563218759371

  3. AMGEN. New Insights in Bone Biology. Introduction to Bone Biology. Recursos digitales. https://www. bonebiology.amgen.com/bone-health/oteoblastsosteoclasts. html (consultado en mayo 2021).

  4. Orthopaedics One. The Orthopaedic knowledge network. 2015. En línea: https://www.orthopaedicsone. com/display/Clerkship/Describe+the+process+of+bone +remodeling.

  5. Zammit AR, Robitaille A, Piccinin AM, Muniz-Terrera G, Hofer SM. Associations between aging related changes in grip strength and cognitive function in older adults: A systematic review. J Gerontol A Biol Sci Med Sci. 2019; 74(4): 519-27. https://doi.org/10.1093/gerona/ gly046

  6. Hart NH, Nimphius S, Rantalainen T, Ireland A, Siafarikas A, Newton RU. Mechanical basis of bone strength: influence of bone material, bone structure and muscle action. J Musculoskelet Neuronal Interact. 2017; 17(3): 114-39. https://pubmed.ncbi.nlm.nih. gov/28860414/

  7. Johansson L, Sundh D, Zoulakis M, Rudang R, Darelid A, Brisby H, et al. The prevalence of vertebral fractures is associated with reduced hip bone density and inferior peripheral appendicular volumetric bone density and structure in older women. J Bone Miner Res. 2018; 33(2): 250–60. https://doi.org/10.1002/jbmr.3297

  8. Marín-Llera JC, Garciadiego-Cázares D, Chimal- Monroy J. Understanding the Cellular and Molecular Mechanisms That Control Early Cell Fate Decisions During Appendicular Skeletogenesis. Front Genet. 2019; 10: 977. https://doi.org/10.3389/fgene.2019.00977

  9. Chan W, Tan Z, To M, Chan D. Regulation and Role of Transcription Factors in Osteogenesis. Int J Mol Sci. 2021; 22(11): 5445. https://doi.org/10.3390/ ijms22115445

  10. Kodama J, Kaito T. Osteoclast Multinucleation: Review of Current Literature. Int J Mol Sci. 2020; 21(16): 5685. https://doi.org/10.3390/ijms21165685

  11. Ono T, Hayashi M, Sasaki F, Nakashima T. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020; 40: 2. https://doi. org/10.1186/s41232-019-0111-3

  12. Boyce BF, Xiu Y, Li J, Xing L, Yao Z. NF-κBMediated Regulation of Osteoclastogenesis. Endocrinol Metab. 2015; 30(1): 35–44. https://doi.org/10.3803/ enm.2015.30.1.35

  13. Morgan EF, Unnikrisnan GU, Hussein AI. Bone Mechanical Properties in Healthy and Diseased States. Ann Rev Biomed Eng. 2018; 20: 119–43. https://doi. org/10.1146/annurev-bioeng-062117-121139

  14. Barberán M, Campusano C, Trincado P, Oviedo S, Brantes S, Sapunar J, et al. Recomendaciones para el uso correcto de densitometría ósea en la práctica clínica. Consenso de la Sociedad Chilena de Endocrinología y Diabetes. Rev Méd Chile. 2018; 146(12): 1471-80. https://dx.doi.org/10.4067/s0034-98872018001201471

  15. Lu J, Shin Y, Yen MS, Sun SS. Peak bone mass and patterns of change in total bone mineral density and bone mineral contents from childhood into young adulthood. J Clin Densitom. 2016; 19(2): 180–91. https://doi. org/10.1016/j.jocd.2014.08.001

  16. Santos L, Elliott-Sale KJ, Sale C. Exercise and bone health across the lifespan. Biogerontology. 2017; 18(6): 931– 46. https://dx.doi.org/10.1007%2Fs10522-017-9732-6

  17. Li K, Wang XF, Li DY, Chen YC, Zhao LJ, Liu XG, et al. The good, the bad, and the ugly of calcium supplementation: a review of calcium intake on human health. Clin Interv Aging. 2018; 13: 2443–52. https:// dx.doi.org/10.2147%2FCIA.S157523

  18. Albergaria BH, Chalem M, Clark P, Messina OD, Pereira R, Vidal LF. Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions. Arch Osteoporos. 2018; 13(1): 90. https://doi.org/10.1007/s11657-018-0505-x

  19. NIH Osteoporosis and Related Bone Diseases National Resource Center. Bone Mass Measurement: What the Numbers Mean. 2018. En línea: https://www.bones.nih. gov/health-info/bone/bone-health/bone-mass-measure.

  20. Secretaría de Gobernación. Proyecto de Norma Oficial Mexicana PROY-NOM-049-SSA2-2017, Para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica de la osteoporosis. Diario Oficial de La Federación. 2017. http://www.dof.gob.mx/ nota_detalle.php?codigo=5496348&fecha=06/09/2017# :~:text=PROYECTO%20de%20Norma%20Oficial%20 Mexicana,vigilancia%20epidemiol%C3%B3gica%20 de%20la%20osteoporosis.

  21. Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV, et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016; 11(1): 25. https://doi.org/10.1007/ s11657-016-0278-z

  22. Kanis JA, Cooper C, Rizzoli R, Reginster JY, et al. (2019). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019; 30(1): 3–44. https://doi.org/10.1007/s00198-018- 4704-5

  23. Odén A, McCloskey EV, Kanis JA, Harvey NC, Johansson H. Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int. 2015;26(9): 2243–8. https://doi.org/10.1007/s00198- 015-3154-6

  24. Aziziyeh R, Amin M, Habib M, Garcia-Perlaza J, Szafranski K, McTavish RK, et al. The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. J Med Econ. 2019; 22(7): 638-44, https://doi.org/10.1080/13696998.2019.1 590843

  25. Clark P, Ramírez-Pérez E, Reyes-López A. Umbrales de evaluación e intervención para la detección de casos en riesgo de osteoporosis y fracturas por fragilidad con FRAX en población mexicana para el primer nivel de salud. Gac Med Mex. 2016; 152(Suppl: 2): 22–31. https://www.medigraphic.com/cgi-bin/new/resumen. cgi?IDARTICULO=68742

  26. Ballane G, Cauley JA, Luckey MM, El-Hajj Fuleihan G. Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int. 2017; 28(5): 1531- 42. https://doi.org/10.1007/s00198-017-3909-3

  27. Tserotas K, Blümel JE. (2019) Menopause research in Latin America. Climacteric. 2019; 22(1): 17-21, https:// doi.org/10.1080/13697137.2018.1540565

  28. Nuti R, Brandi ML, Checchia G, Di Munno O, Dominguez L, Falaschi P, et al. Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med. 2019; 14(1): 85-102, https://doi.org/10.1007/s11739- 018-1874-2

  29. Mendoza Romo MA, Escalante Pulido JM, Martínez Zúñiga R, Ramírez Arriola MC. Osteoporosis en mexicanas mayores de 40 años. Determinación por densitometría periférica. Rev Med IMSS. 2003; 41(3): 193–202. https://www.medigraphic.com/pdfs/imss/im- 2003/im033b.pdf

  30. Rosales-Aujang E, Muñoz-Enciso JM, Arias-Ulloa R. Prevalencia de osteopenia y osteoporosis en mujeres posmenopáusicas y su relación con factores de riesgo. Ginecol Obstet Mex. 2014; 82(4): 223-28. https://www.medigraphic.com/cgi-bin/new/resumen. cgi?IDARTICULO=48760

  31. Cooper C, Ferrari S. IOF Compendium of Osteoporosis. 2019. En línea: https://bit.ly/3pygUGo

  32. Cauley JA. Defining ethnic and racial differences in osteoporosis and fragility fractures. Clin Orthop Relat Res. 2011; 469(7): 1891–9. https://doi.org/10.1007/ s11999-011-1863-5

  33. Jin YZ, Lee JH, Xu B, Cho M. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2019; 20: 399, https://doi.org/10.1186/s12891- 019-2769-8

  34. Okamoto H, Shibazaki N, Yoshimura T, Uzawa T, Sugimoto T. Association between elcatonin use and cancer risk in Japan: A follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis. Osteoporos Sarcopenia. 2020; 6(1): 15–19, https://doi.org/10.1016/j.afos.2020.02.001

  35. Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, Russo LA, Alexandersen P, et al. A randomized, doubleblind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Bone. 2016; 91: 122–9. https://doi.org/10.1016/j.bone.2016.07.019

  36. Wells G, Chernoff J, Gilligan JP, Krause DS. Does salmon calcitonin cause cancer? A review and metaanalysis. Osteoporos Int. 2016; 27(1): 13–9. https://doi. org/10.1007/s00198-015-3339-z

  37. García-Hernández P, Carranza-Lira S, Motta-Martínez E. Apego al ibandronato mensual en mujeres mexicanas y chilenas con osteoporosis, con o sin una estrategia de bio-retroalimentación. Ginecol Obstet Mex. 2010; 78(6): 322–8. https://www.medigraphic.com/cgi-bin/new/ resumen.cgi?IDARTICULO=27254

  38. Liang S, Hu S, Guo H, Dong L, Liu G, Liu Y. Ibandronate sodium and zoledronate sodium in the treatment of senile osteoporosis: efficacy, impact on quality of life and costeffectiveness analysis. Am J Transl Res. 2021; 13(3): 1764-71, http://www.ncbi.nlm.nih.gov/pmc/articles/ pmc8014411/

  39. Qayoom I, Raina DB, Širka A, Tarasevičius Š, Tägil M, Kumar A, et al. Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair: A review. Bone Joint Res. 2018; 7(10): 548–60. https://doi. org/10.1302/2046-3758.710.BJR-2018-0015.R2

  40. National Center for Biotechnology Information. PubChem Database. https://pubchem.ncbi.nlm.nih.gov/ compound/(accessed on May, 2020).

  41. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell R. (2019). Pharmacology of bisphosphonates. Brit J Clin Pharmacol. 2019; 85(6): 1052–62, https://doi. org/10.1111/bcp.13867

  42. Qiu YQ. KEGG Pathway Database. In: Dubitzky W, Wolkenhauer O, Cho KH, Yokota H. (Eds.), Encyclopedia of Systems Biology (pp. 1068–1069). 2013. Springer New York.

  43. Roy M, Roux S. Rab GTPases in Osteoclastic Bone Resorption and Autophagy. Int J Mol Sci. 2020; 21(20): 7655. https://doi.org/10.3390/ijms21207655

  44. Huang KC, Cheng CC, Chuang PY, Yang TY. The effects of zoledronate on the survival and function of human osteoblast-like cells. BMC Musculoskelet Disord. 2015; 16(355): 1–7. https://doi.org/10.1186/s12891-015-0818- 5

  45. Sosa Henríquez M, Gómez de Tejada Romero MJ. El correcto cumplimiento del tratamiento para la osteoporosis: aún nos queda mucho por hacer. Rev Osteoporos Metab Miner. 2016; 8(1): 3–4. https://scielo. isciii.es/scielo.php?script=sci_arttext&pid=S1889- 836X2016000100001

  46. Yao L, Wang H, Dong W, Liu Z, Mao H. Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: A meta-analysis. Medicine. 2017; 96(3): e5861-7. https://doi.org/10.1097/ md.0000000000005861

  47. Center for Drug Evaluation and Research. En línea: fhttps://www.accessdata.fda.gov/drugsatfda_docs/ nda/2008/021455Orig1s007.pdf




2020     |     www.medigraphic.com